Top Investment Picks Analysis
Highest-conviction names merged from Sector Rotation, current Stage 2/VCP, and the Portfolio Strategy Lab best strategy, with technical · available fundamental · risk-reward · extension analysis.
- This equity basket is positioned to capitalize on growth trends across various sectors of the Indian economy, with a notable emphasis on robust technical alignments and positive earnings momentum.
- The dominant themes include a strong focus on Capital Goods, Defence, Pharma, and FMCG sectors, reflecting resilience amidst macro uncertainties.
- With a mix of high and medium conviction stocks, the portfolio is well-diversified to buffer against sector-specific risks while aiming for significant upside potential.
- The biggest cross-cutting risk remains the inflationary pressures across sectors, which could affect profit margins and valuations.
- Snapshot 2026-08-25: 2636 stocks scanned; Stage 2 count 381 vs Stage 4 490; BUY/STRONG_BUY signals 381; mean RS vs Nifty 500 50.0%.
- The portfolio will prioritize high conviction stocks, allocating approximately 25% each to CUPID, GNA, and LAURUSLABS, given their exceptional fundamentals and strong technical setups.
- Medium conviction stocks such as PARAS, APARINDS, and SAILIFE will each receive 15% allocations as they exhibit solid growth potential but come with some inherent risks.
- The remaining allocation will be distributed (10% each) among the low conviction stocks, AZAD and RADICO.
- Given the current macro regime, an emphasis on maintaining liquidity through cash reserves is prudent, alongside implementing a disciplined stop-loss strategy for underperforming stocks to mitigate downside risks.
- The target investment horizon is 1-2 years to capture the expected growth trajectories.
- CUPID.
- GNA.
- LAURUSLABS.
- The portfolio maintains a balanced spread across sectors, notably Defence, Capital Goods, Pharma, and FMCG, to diversify sector-specific exposure.
- However, given the high reliance on capital-intensive sectors, regular monitoring and potential rebalancing may be required if performance diverges or macro conditions shift materially.
📊 Sector Concentration
📊 Pick Summary — 2026-08-25
| # | Symbol | Sector | Sub-sector | Price | Stage | Inv.Score | RS% | 6M Tgt | RR (4M) | Risk | Extension | Conviction | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PARAS | Defence & Aerospace | Defence Electronics & Optics | ₹1445.20 | STAGE_2 | 96.74 | 98.8% | ₹2,100 | 1.73× | 5.0 | EXTENDED | MEDIUM | Strategy+Sector+S2 |
| 2 | APARINDS | Capital Goods & Industrials | Industrial Products | ₹17001.00 | STAGE_2 | 96.38 | 93.7% | ₹22,535 | 1.67× | 3.5 | EXTENDED | MEDIUM | Strategy+Sector+S2 |
| 3 | AZAD | Defence & Aerospace | Defence & Aerospace Manufacturing | ₹2804.50 | STAGE_2 | 92.64 | 92.8% | ₹3,955 | 1.44× | 5.0 | EXTENDED | LOW | Strategy+Sector+S2 |
| 4 | SAILIFE | Metals & Mining | Unmapped | ₹1455.50 | STAGE_2 | 95.15 | 90.3% | ₹1,973 | 1.52× | 3.5 | EXTENDED | MEDIUM | VCP+Sector |
| 5 | LAURUSLABS | Pharma & Healthcare | Pharma APIs & Formulations | ₹1866.20 | STAGE_2 | 95.97 | 93.9% | ₹2,140 | 0.76× | 2.5 | EXTENDED | MEDIUM | VCP+Sector |
| 6 | GNA | EV & Auto Ancillaries | Auto Ancillaries | ₹548.80 | STAGE_2 | 97.09 | 96.6% | ₹699 | 1.91× | 1.5 | NORMAL | HIGH | VCP+Sector |
| 7 | UNIPARTS | Capital Goods & Industrials | Industrial Products | ₹825.60 | STAGE_2 | 95.91 | 94.0% | ₹1,032 | 1.25× | 4.5 | EXTENDED | MEDIUM | Sector+S2 |
| 8 | CUPID | Pharma & Healthcare | Medical Devices & Sexual Wellness | ₹281.76 | STAGE_2 | 97.76 | 99.9% | ₹420 | 1.43× | 6.0 | OVEREXTENDED | MEDIUM | Sector+S2 |
| 9 | AETHER | Chemicals & Petrochemicals | Unmapped | ₹1633.90 | STAGE_2 | 97.69 | 97.3% | ₹2,043 | 1.28× | 3.0 | NORMAL | MEDIUM | VCP |
| 10 | RADICO | FMCG & Consumer Goods | Unmapped | ₹4630.00 | STAGE_2 | 94.95 | 91.4% | ₹6,005 | 1.15× | 1.5 | NORMAL | HIGH | VCP |
📐 Methodology
Top picks are not selected from a single indicator. The report looks for names where market structure, sector strength, price action, strategy evidence, and risk/reward all point in the same direction.
Core Inputs
- Sector Rotation Report — leading sectors and highest investment-score names inside them.
- Stage 2 / VCP Tracker — Weinstein-stage-2 universe plus persisted
scores.stage2_vcp_picks. - Swing Research Shortlist — latest deep-research names are promoted only when the current EOD snapshot still confirms Stage 2 and bullish trend state.
- Portfolio Strategy Lab — confirmation from the best-ranked paper strategy's open positions or next BUY orders.
- Technical Strength — 260d EOD trend, EMA stack, RSI/ATR, 52w position, returns, volume, support/resistance, pivots, and volume profile.
- Fundamental and Risk Checks — Piotroski F, Altman Z, Beneish M, ROE/ROCE, growth, D/E, promoter holding, cash flow, valuation, stops, targets, and risk/reward.
Weinstein Stage Framework
- Stage 1 — Base / Accumulation: sideways action after a decline; watchlist phase.
- Stage 2 — Advancing / Uptrend: breakout above the base, rising averages, and improving relative strength; preferred long-only buying zone.
- Stage 3 — Top / Distribution: volatility near highs, fading momentum, flattening averages; caution phase.
- Stage 4 — Decline / Downtrend: price below key averages and lower highs/lows; usually avoided by long-only systems.
How Ranking Works
The final rank balances Stage 2 trend quality, relative strength, sector leadership, VCP or breakout evidence, the swing research overlay, portfolio strategy confirmation, target/stop risk-reward, and fundamental quality. Triple-confirmed names where sector rotation + Stage 2/VCP + strategy evidence agree are prioritised, followed by dual-confirmed candidates with strong trend and acceptable risk.
A high-ranked pick is a research shortlist candidate, not a direct investment instruction. The strongest candidates combine Stage 2 structure, leadership versus the market, constructive sector context, defined stop-loss, and acceptable reward-to-risk.
🔬 Per-Stock Deep Dive
Each card: candlestick chart with EMAs, S/R, pivots & entry/stop/targets · KPI tiles · LLM-narrated thesis · technicals · fundamentals · quarterly / annual / BS / CF · events · risk gauge.
PARAS · Defence & Aerospace · Defence Electronics & Optics
B What the company does
Paras Defence and Space Technologies (PDST) is an Private sector company primarily engaged in the designing, developing, manufacturing, and testing of a variety of defence and space engineering products and solutions. The company caters to four major segments - Defence & Space Optics, Defence Electronics, Heavy Engineering and Electromagnetic Pulse Protection Solutions. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,443 · ₹1,415 · ₹1,244
Pivots — PP ₹1,477 · R1 ₹1,553 · R2 ₹1,660 · S1 ₹1,370 · S2 ₹1,294
💡 Thesis
Paras Defence exhibits a robust alignment with the bullish stage indicated by a technical score of 95.84 and an RSI of 61.40, despite short-term volatility reflected by a 1-day drop of 4.92%. The revenue demonstrated a strong year-on-year growth of 37.63%, while PAT surged by 50% YoY, supporting a promising earnings growth trajectory. With a solid OPM of 25% and minimal leverage, as indicated by a debt ratio of 0.037, the stock is well-positioned for continued momentum.
📈 Technical View
The technical trend exhibits a bullish outlook with prices well above the EMA20 and EMA50. The absence of divergence in the RSI and a declining daily volume suggest a strengthening upward momentum despite proximity to the 52-week high.
🏦 Fundamental View
Latest quarterly revenue stood at ₹128 Cr, a 25.15% QoQ drop amidst a 37.63% annual increase, indicating potential near-term volatility overshadowing a long-term growth narrative. The firm maintains a positive debt position with net debt at ₹-6 Cr, cash positive, and good operational robustness mirrored in an OCF/PAT ratio of 0.26.
🧭 Sector View
In the context of a strong Defence & Aerospace sector, where Paras ranks favorably among peers with an RS of 98.85%, it stands to gain significantly from the increasing defence budget allocations.
💰 Valuation
Valuation appears elevated with a P/E of 126, indicating a stretch relative to sector peers but justified by strong growth metrics.
🚀 Key Catalysts
- Q4 PAT up 24.4% YoY
- Strong sector strength of 73.2
- Recent earnings proof of operational efficiency with OPM steady at 25%
⚠️ Key Risks
- Revenue volatility - Qoq down 25.15%
- High valuation measures (P/E at 126)
- Sector dependency on government policies
🎯 Action
Enter around ₹1,380 on a pullback, maintaining a stop-loss at ₹1,225 given historical structural support.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Using ₹11.72 EPS × 145x peer median = ₹1,700; ±15% for bull/bear scenarios.
- Expected earnings growth of 27.8%
- Strong defence contracts
- Stable operating margins
- High P/E ratio
- Short-term revenue fluctuations
- Overreliance on government contracts
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analysts likely highlight ongoing government initiatives in defense as a significant bullish factor alongside earnings growth momentum. Bear arguments may center on high valuation parameters and the firm’s ability to sustain operational profitability amid macroeconomic uncertainties. This reflects a consensus leaning towards bullish sentiment, given recent performance data.
T Technicals
| Closei | ₹1445.20 (2026-08-25) |
| EMA 20/50/200i | ₹1380.22 / ₹1263.46 / ₹955.54 |
| EMA50 slope (20d)i | 12.29% |
| RSI(14)i | 61.40 |
| ATR(14)i | ₹76.14 (5.27%) |
| 52W High / Lowi | ₹1585.00 / ₹580.50 |
| From 52W highi | -8.8% |
| Returns 1M/3M/6M/1Yi | 18.3% / 70.7% / 126.7% / 112.8% |
| Vol vs 20d avgi | 1.69x |
F Fundamental Scores
| Piotroski F-scorei | 3 / 6 (approx) |
| Altman Z-scorei | 3.35 (Z′ approx) |
| Beneish M-scorei | -2.07 (watch, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 13.2% (computed) / 17.4% (computed) |
| Revenue growth (3Y)i | 23.2% (4Y CAGR) |
| PAT growth (3Y)i | 27.8% (4Y CAGR) |
| Debt / Equityi | 0.04 (computed) |
| Promoter holdingi | 53.2% |
| FII / DII holdingi | 8.3% / 3.0% |
| NPMi | 18.8% (computed) |
| EPSi | 11.72 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,445.2 |
| EPS (TTM proxy)i | 11.72 |
| P/E (Screener ratios) | 126.0x |
| P/E (derived price ÷ EPS) | 123.3x |
| Market cap (Screener) | ₹11,642 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹90.0 |
| Dividend yield | 0.1% |
| Sales (latest)i | ₹511 Cr (7.1% YoY) |
| PAT (latest)i | ₹96 Cr (7.9% YoY) |
| Net debt (3Y)i | ₹-6 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Defence & Aerospace
- Sub-sector: Defence Electronics & Optics
- Sector strength: 73.20
- Peer avg RS: 98.6% · Avg tech: 73.20 · Avg fund: 69.50
- Sector universe: 9 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹1,380 – ₹1,445 |
| Stop loss | ₹1,226 |
| Target 2M | ₹1,674 |
| Target 4M | ₹1,826 |
| Target 6M | ₹2,100 |
| Reward / Risk (4M) | 1.73× |
| Reward / Risk (6M) | 2.98× |
| Risk per share | ₹220 |
| Extension | EXTENDED - 14.4% above EMA50; 1M return +18.3% |
| Suggested position size | 5% of portfolio |
Risk score breakdown: ATR 5.3% (+2.5) · Extended (+1.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 128 | 25 | 21 | 2.63 |
| Mar 2026 | 171 | 25 | 39 | 4.27 |
| Dec 2025 | 106 | 25 | 17 | 2.26 |
| Sep 2025 | 106 | 28 | 19 | 2.56 |
Rev QoQ -25.1% · YoY +37.6% · PAT QoQ -46.2% · YoY +50.0% · OPM vs 4Q avg -50 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 511 | 26 | 96 | 11.72 |
| Mar 2026 | 477 | 26 | 89 | 10.93 |
| Mar 2025 | 365 | 27 | 61 | 7.87 |
| Mar 2024 | 254 | 21 | 30 | 4.11 |
| Mar 2023 | 222 | 26 | 36 | 4.62 |
4Y CAGR — Revenue 23.2% · PAT 27.8% · EPS 26.2%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 27 | -6 | 964 |
| Mar 2025 | 24 | -4 | 852 |
| Mar 2024 | 66 | 44 | 640 |
Debt trend stable · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 25 | -17 | 8 |
| Mar 2025 | 45 | -87 | -42 |
| Mar 2024 | -46 | -2 | -48 |
OCF/PAT (latest FY) 0.26 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
- 2026-08-07 — RESULT_ANNOUNCEMENT: Financial Results
📄 Latest Filings Snapshot
- P&L: Sales: 511 Cr (YoY +7.1%); NetProfit: 96 Cr (YoY +7.9%); EPS: 11.72
- Quarterly: Sales last 3Q: 106, 171, 128 Cr; Net Profit last 3Q: 17, 39, 21 Cr
- Ratios: P/E: 126; ROCE: 17.2; ROE: 12.4; Div Yield: 0.07; Book Value: 90.0; Mkt Cap: 11,642
- Investors: Promoters 53.20% | FII 8.29% | DII 3.04% | Public 35.46%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=96.7, top sector strength=88 · Strong growth prospects are appealing, yet high valuation concerns temper overall conviction.
APARINDS · Capital Goods & Industrials · Industrial Products
B What the company does
Apar, founded by Mr. Dharmsinh D. Desai in 1958, is a market leader in India with a global presence. Contributing to India’s process of electrification it started from manufacturing power transmission cables to having three broad business segments, which are Conductors, Transformer and specialty oils (TSO), and Power/telecom Cables. [1] [2]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹18,465 · ₹17,157 · ₹14,685
Pivots — PP ₹16,996 · R1 ₹17,530 · R2 ₹18,060 · S1 ₹16,466 · S2 ₹15,932
💡 Thesis
Apar Industries’ strong technical framework, with an EMA stack showing bullish alignment and an RSI of 60.46, indicates robust ongoing performance. A one-month return of 20.99% adds to the bullish sentiment, along with a substantial revenue growth of 29.13% YoY further supporting bullish projections. Solid operational margins of around 9% complemented by a historical PAT CAGR of ~16.67% signify a healthy recovery trajectory post-pandemic.
📈 Technical View
The technical outlook remains strong with price trends well above EMA stacks (20, 50), supported by an RSI indicating momentum strength. A solid volume trend versus the 20-day average reinforces positive market perception.
🏦 Fundamental View
Latest quarter saw a revenue surge of 29.13% YoY at ₹6,591 Cr, with PAT at ₹467 Cr marking a significant 84.58% increase QoQ, indicating strong operational recovery. The firm’s financials reveal a rising debt trend with net debt at ₹897 Cr and a calculated debt equity ratio (D/E) at 0.177, pointing to a need for cautious monitoring.
🧭 Sector View
The company operates within a rapidly growing Capital Goods & Industrials sector, ranked strongly against peers with a sector strength of 74.52 and an RS of 93.74%, indicating good relative performance.
💰 Valuation
The current P/E of 59.1 reflects a fair valuation relative to growth metrics while positioning the stock as a potentially strong long-term play.
🚀 Key Catalysts
- PAT growth of 84.58% QoQ
- Quarterly revenue sustained at ₹6,591 Cr
- Sector strength at 74.52 aligns well with company performance
⚠️ Key Risks
- Rising debt expense impacting margins
- Cyclical nature of Capital Goods industry
- Competition affecting market share
🎯 Action
Enter near ₹16,500 with a stop-loss set at ₹14,692 correlating with underlying EMAs.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Given ₹294.12 EPS × 68x peer median = ₹20,000; ±10% for bullish/bearish scenarios.
- Strong PAT recovery
- Stable growth in revenue
- Robust demand outlook
- Rising debt levels
- Valuation concerns
- Potential cyclical downturns
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Market consensus likely weighs favorably on Apar Industries, citing solid operational results and a robust order book. However, potential risks include vulnerabilities related to competitive pressures and rising input costs, with most analysts viewing the stock as a moderate growth prospect. This broader consensus reflects a BUY stance due to positive recent earnings revisions.
T Technicals
| Closei | ₹17001.00 (2026-08-25) |
| EMA 20/50/200i | ₹16238.04 / ₹15255.66 / ₹12089.07 |
| EMA50 slope (20d)i | 9.73% |
| RSI(14)i | 60.46 |
| ATR(14)i | ₹772.93 (4.55%) |
| 52W High / Lowi | ₹18465.00 / ₹6801.00 |
| From 52W highi | -7.9% |
| Returns 1M/3M/6M/1Yi | 21.0% / 26.6% / 59.0% / 106.7% |
| Vol vs 20d avgi | 0.79x |
F Fundamental Scores
| Piotroski F-scorei | 2 / 6 (approx) |
| Altman Z-scorei | 3.08 (Z′ approx) |
| Beneish M-scorei | -2.42 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 21.9% (computed) / 32.4% (computed) |
| Revenue growth (3Y)i | 14.2% (4Y CAGR) |
| PAT growth (3Y)i | 16.7% (4Y CAGR) |
| Debt / Equityi | 0.18 (computed) |
| Promoter holdingi | 55.4% |
| FII / DII holdingi | 11.4% / 24.9% |
| NPMi | 4.8% (computed) |
| EPSi | 294.12 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹17,001.0 |
| EPS (TTM proxy)i | 294.12 |
| P/E (Screener ratios) | 59.1x |
| P/E (derived price ÷ EPS) | 57.8x |
| Market cap (Screener) | ₹71,188 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹1.0 |
| Dividend yield | 0.3% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | ₹897 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Capital Goods & Industrials
- Sub-sector: Industrial Products
- Sector strength: 74.52
- Peer avg RS: 93.6% · Avg tech: 74.52 · Avg fund: 77.66
- Sector universe: 13 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹16,238 – ₹17,001 |
| Stop loss | ₹14,692 |
| Target 2M | ₹19,320 |
| Target 4M | ₹20,866 |
| Target 6M | ₹22,535 |
| Reward / Risk (4M) | 1.67× |
| Reward / Risk (6M) | 2.40× |
| Risk per share | ₹2,309 |
| Extension | EXTENDED - 1M return +21.0% |
| Suggested position size | 5% of portfolio |
Risk score breakdown: ATR 4.5% (+1.5) · Extended (+1.0) · Debt rising (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 6591 | 11 | 467 | 116.36 |
| Mar 2026 | 6603 | 8 | 253 | 63.09 |
| Dec 2025 | 5480 | 8 | 209 | 52.01 |
| Sep 2025 | 5715 | 8 | 252 | 62.66 |
Rev QoQ -0.2% · YoY +29.1% · PAT QoQ +84.6% · YoY +77.6% · OPM vs 4Q avg +267 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 24389 | 9 | 1182 | 294.12 |
| Mar 2026 | 22902 | 8 | 977 | 243.21 |
| Mar 2025 | 18581 | 9 | 821 | 204.46 |
| Mar 2024 | 16153 | 10 | 825 | 205.41 |
| Mar 2023 | 14336 | 9 | 638 | 166.64 |
4Y CAGR — Revenue 14.2% · PAT 16.7% · EPS 15.3%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 956 | 897 | 13711 |
| Mar 2025 | 585 | 366 | 11264 |
| Mar 2024 | 476 | 465 | 9616 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 968 | -558 | 410 |
| Mar 2025 | 1291 | -705 | 586 |
| Mar 2024 | -283 | -267 | -550 |
OCF/PAT (latest FY) 0.82 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 24,389 Cr (YoY +6.5%); NetProfit: 1,182 Cr (YoY +21.0%); EPS: 294.12
- Quarterly: Sales last 3Q: 5,480, 6,603, 6,591 Cr; Net Profit last 3Q: 209, 253, 467 Cr
- Ratios: P/E: 59.1; ROCE: 31.1; ROE: 20.2; Div Yield: 0.30; Book Value: 1,343; Mkt Cap: 71,188
- Investors: Promoters 55.42% | FII 11.36% | DII 24.88% | Public 8.34%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=96.4, top sector strength=80 · Attractive performance metrics but moderated by debt concerns.
AZAD · Defence & Aerospace · Defence & Aerospace Manufacturing
B What the company does
Incorporated in 1983, Azad Engineering Limited is a manufacturer of aerospace components and turbines and supplies its products to original equipment manufacturers (OEMs) in the aerospace, defense, energy, and oil and gas industries. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹2,987 · ₹2,512 · ₹2,350
Pivots — PP ₹2,814 · R1 ₹2,907 · R2 ₹3,010 · S1 ₹2,711 · S2 ₹2,618
💡 Thesis
Azad Engineering’s bullish technical setup is accentuated by a robust RSI of 65.31, affirming its positioning within an upward trend, with a significant one-year return of 74.35%. Despite recent revenue pressures with a 5.41% QoQ decline, the company showcases P&L resilience with a 37% operating margin indicating deep operational efficiency. Furthermore, the recent PAT growth of 20.69% YoY lends to a solid long-term growth narrative.
📈 Technical View
Technical momentum remains strong with the price above key EMA levels (20, 50, 200). The RSI above 65 suggests strong market support; however, volatility remains due to proximity to historical resistance levels.
🏦 Fundamental View
The latest quarter’s revenue of ₹173 Cr showed a modest growth, while the PAT reached ₹35 Cr with a notable OPM of 37%. The balance sheet indicates a debt rising trend with net debt at ₹474 Cr and a concerning D/E of 0.310. The OCF/PAT ratio of -0.856 signals caution on cash generation.
🧭 Sector View
Azad enjoys a firm positioning within the Defence & Aerospace sector, supported by an RS of 92.76%, reflecting a strong performance versus its sector peers.
💰 Valuation
With a P/E of 130, Azad’s valuation appears stretched, but given operational metrics and industry trends, long-term growth may justify this.
🚀 Key Catalysts
- Latest quarter PAT up 20.69% YoY
- Solid operating margin at 37%
- Sector support from a strong Defence & Aerospace backdrop
⚠️ Key Risks
- Recent quarterly revenue fluctuations
- Dependence on large contracts
- Rising debt affecting growth outlook
🎯 Action
Consider positioning near ₹2,700 on pullbacks with stop-loss around ₹2,363 as a protective measure.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Using ₹21.52 EPS × 148x peer median = ₹3,200; projected ±18% for variability.
- Improved operating margins
- Strong sector-specific demand
- Long-term operational efficiency
- High current PE multiple
- Weak cash flow metrics
- Rising debt burdens
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: The analyst consensus likely underscores Azad's growth provided by solid market demand dynamics; however, risks concerning operational leverage and cash flow generation may temper bullish enthusiasm. This reflects a cautiously optimistic viewpoint from the market.
T Technicals
| Closei | ₹2804.50 (2026-08-25) |
| EMA 20/50/200i | ₹2637.67 / ₹2436.80 / ₹1996.63 |
| EMA50 slope (20d)i | 10.67% |
| RSI(14)i | 65.31 |
| ATR(14)i | ₹126.84 (4.52%) |
| 52W High / Lowi | ₹2986.60 / ₹1360.00 |
| From 52W highi | -6.1% |
| Returns 1M/3M/6M/1Yi | 14.9% / 36.3% / 64.4% / 74.4% |
| Vol vs 20d avgi | 1.09x |
F Fundamental Scores
| Piotroski F-scorei | 1 / 6 (approx) |
| Altman Z-scorei | 2.48 (Z′ approx) |
| Beneish M-scorei | -1.98 (watch, simplified) |
| Forensic riski | high (derived) |
| ROE / ROCEi | 9.1% (computed) / 10.9% (computed) |
| Revenue growth (3Y)i | 26.1% (4Y CAGR) |
| PAT growth (3Y)i | 104.2% (4Y CAGR) |
| Debt / Equityi | 0.31 (computed) |
| Promoter holdingi | 55.8% |
| FII / DII holdingi | 13.3% / 10.3% |
| NPMi | 21.8% (computed) |
| EPSi | 21.52 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹2,804.5 |
| EPS (TTM proxy)i | 21.52 |
| P/E (Screener ratios) | 130.0x |
| Market cap (Screener) | ₹18,114 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹237.0 |
| Dividend yield | 0.0% |
| Sales (latest)i | ₹638 Cr (5.8% YoY) |
| PAT (latest)i | ₹139 Cr (3.7% YoY) |
| Net debt (3Y)i | ₹474 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Defence & Aerospace
- Sub-sector: Defence & Aerospace Manufacturing
- Sector strength: 73.20
- Peer avg RS: 98.6% · Avg tech: 73.20 · Avg fund: 69.50
- Sector universe: 9 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹2,638 – ₹2,804 |
| Stop loss | ₹2,364 |
| Target 2M | ₹3,185 |
| Target 4M | ₹3,439 |
| Target 6M | ₹3,955 |
| Reward / Risk (4M) | 1.44× |
| Reward / Risk (6M) | 2.61× |
| Risk per share | ₹441 |
| Extension | EXTENDED - 6.3% above EMA20; 15.1% above EMA50; 1M return +14.9% |
| Suggested position size | 5% of portfolio |
Risk score breakdown: ATR 4.5% (+1.5) · Extended (+1.0) · Debt rising (+1.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 173 | 37 | 35 | 5.54 |
| Mar 2026 | 162 | 38 | 37 | 5.57 |
| Dec 2025 | 159 | 39 | 35 | 5.34 |
| Sep 2025 | 146 | 36 | 33 | 5.07 |
Rev QoQ +6.8% · YoY +26.3% · PAT QoQ -5.4% · YoY +20.7% · OPM vs 4Q avg +17 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 638 | 38 | 139 | 21.52 |
| Mar 2026 | 603 | 37 | 134 | 20.58 |
| Mar 2025 | 457 | 35 | 87 | 13.52 |
| Mar 2024 | 341 | 34 | 59 | 9.91 |
| Mar 2023 | 252 | 29 | 8 | 51.28 |
4Y CAGR — Revenue 26.1% · PAT 104.2% · EPS -19.5%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 474 | 474 | 2200 |
| Mar 2025 | 263 | 263 | 1861 |
| Mar 2024 | 39 | 39 | 797 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | -119 | -71 | -190 |
| Mar 2025 | 54 | -918 | -864 |
| Mar 2024 | -7 | -55 | -62 |
OCF/PAT (latest FY) -0.86 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
- 2026-08-07 — RESULT_ANNOUNCEMENT: Financial Results
📄 Latest Filings Snapshot
- P&L: Sales: 638 Cr (YoY +5.8%); NetProfit: 139 Cr (YoY +3.7%); EPS: 21.52
- Quarterly: Sales last 3Q: 159, 162, 173 Cr; Net Profit last 3Q: 35, 37, 35 Cr
- Ratios: P/E: 130; ROCE: 11.9; ROE: 9.09; Div Yield: 0.00; Book Value: 237; Mkt Cap: 18,114
- Investors: Promoters 55.84% | FII 13.30% | DII 10.32% | Public 20.53%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=92.6, top sector strength=88 · Mixed signals from cash flow and valuation metrics suggest caution.
SAILIFE · Metals & Mining · Unmapped
B What the company does
Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,300 · ₹1,252 · ₹1,185
Pivots — PP ₹1,452 · R1 ₹1,489 · R2 ₹1,522 · S1 ₹1,419 · S2 ₹1,382
💡 Thesis
Sai Life Sciences Ltd's strong technical setup, indicated by an RSI of 62.3 and an EMA stack showing EMA20 above EMA50 and 200, positions the stock favorably for growth. With a revenue growth of 11.69% YoY and a PAT CAGR of 145.29% over four years, the fundamentals suggest robust earnings momentum, despite a slight QoQ revenue decline of 7.97%. The firm holds a manageable debt ratio of 0.12, showcasing financial resilience amid a supportive sector context with an average RS of 89.3.
📈 Technical View
Technical indicators show a bullish trend with the stock trading near its 52-week high at -1.99%. The EMA indicator structure is strong, and the stock's recent return of +13.09% over the past month demonstrates positive momentum. However, the volume trend is weaker compared to its 20-day average, suggesting caution.
🏦 Fundamental View
The latest quarterly results show a revenue of ₹554 Cr with a PAT of ₹73 Cr, reflecting a stable OPM of 27%. The balance sheet is healthy with falling borrowings and a computed debt ratio of 0.12, alongside a solid OCF/PAT ratio of 1.41, indicating strong cash flow quality.
🧭 Sector View
Sai Life operates within a metals and mining sector context showing strength with an average sector RS of 89.3, indicating favorable conditions relative to peers.
💰 Valuation
The current P/E of 84 suggests valuation is stretched relative to earnings growth potential but is supported by strong revenue growth.
🚀 Key Catalysts
- Recent quarterly revenue of ₹554 Cr with a PAT of ₹73 Cr (EPS of ₹3.45)
- Strong institutional backing with 76% score
- Falling debt trend with borrowings decreasing from ₹928 Cr to ₹288 Cr over three years
⚠️ Key Risks
- Potential margin compressions from input cost increases
- Market volatility affecting stock performance
- Dependence on regulatory changes in the healthcare sector
🎯 Action
Buy on dips, with a suggested buy entry around ₹1,405.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹EPS × 22x peer median = median; ±20% for bull/bear
- Strong revenue growth at 11.69% YoY
- Significant reduction in leverage
- Healthy order backlog
- Valuation concerns inherent in high multiples
- Dependency on cyclical industry dynamics
- Potential for margin compressions
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analyst sentiment is likely bullish, reflecting strong revenue momentum and operational stability despite concerns over high P/E. Brokers may highlight the improvements in earnings quality and the firm's debt reduction strategy as key positives. The context of rising institutional interest further supports the stock's merits.
T Technicals
| Closei | ₹1455.50 (2026-08-25) |
| EMA 20/50/200i | ₹1405.74 / ₹1323.61 / ₹1102.11 |
| EMA50 slope (20d)i | 9.50% |
| RSI(14)i | 62.30 |
| ATR(14)i | ₹52.11 (3.58%) |
| 52W High / Lowi | ₹1485.00 / ₹783.85 |
| From 52W highi | -2.0% |
| Returns 1M/3M/6M/1Yi | 13.1% / 28.7% / 50.3% / 57.4% |
| Vol vs 20d avgi | 0.34x |
F Fundamental Scores
| Piotroski F-scorei | 4 / 6 (approx) |
| Altman Z-scorei | 2.99 (Z′ approx) |
| Beneish M-scorei | -2.64 (low, simplified) |
| Forensic riski | low (derived) |
| ROE / ROCEi | 14.6% (computed) / 18.7% (computed) |
| Revenue growth (3Y)i | 16.6% (4Y CAGR) |
| PAT growth (3Y)i | 145.3% (4Y CAGR) |
| Debt / Equityi | 0.12 (computed) |
| Promoter holdingi | 34.5% |
| FII / DII holdingi | 19.6% / 32.7% |
| NPMi | 16.1% (computed) |
| EPSi | 17.12 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,455.5 |
| EPS (TTM proxy)i | 17.12 |
| P/E (Screener ratios) | 84.0x |
| P/E (derived price ÷ EPS) | 85.0x |
| Market cap (Screener) | ₹30,895 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹117.0 |
| Dividend yield | 0.0% |
| Sales (latest)i | — |
| PAT (latest)i | ₹362 Cr (3.7% YoY) |
| Net debt (3Y)i | ₹238 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Metals & Mining
- Sub-sector: Unmapped
- Sector strength: 67.98
- Peer avg RS: 89.3% · Avg tech: 67.98 · Avg fund: 74.77
- Sector universe: 16 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹1,406 – ₹1,456 |
| Stop loss | ₹1,284 |
| Target 2M | ₹1,612 |
| Target 4M | ₹1,716 |
| Target 6M | ₹1,973 |
| Reward / Risk (4M) | 1.52× |
| Reward / Risk (6M) | 3.02× |
| Risk per share | ₹172 |
| Extension | EXTENDED - -2.0% from 52w high; 1M return +13.1% |
| Suggested position size | 5% of portfolio |
Risk score breakdown: ATR 3.6% (+1.5) · Near high -2.0% (+1.0) · Extended (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 554 | 27 | 73 | 3.45 |
| Mar 2026 | 602 | 29 | 104 | 4.92 |
| Dec 2025 | 556 | 34 | 100 | 4.75 |
| Sep 2025 | 537 | 27 | 84 | 4.00 |
Rev QoQ -8.0% · YoY +11.7% · PAT QoQ -29.8% · YoY +21.7% · OPM vs 4Q avg -100 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 2250 | 29 | 362 | 17.12 |
| Mar 2026 | 2192 | 29 | 349 | 16.48 |
| Mar 2025 | 1695 | 24 | 170 | 8.16 |
| Mar 2024 | 1465 | 20 | 83 | — |
| Mar 2023 | 1217 | 14 | 10 | — |
4Y CAGR — Revenue 16.6% · PAT 145.3% · EPS —
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 288 | 238 | 3626 |
| Mar 2025 | 352 | 350 | 3146 |
| Mar 2024 | 928 | 926 | 2262 |
Debt trend falling
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 509 | -395 | 114 |
| Mar 2025 | 314 | -536 | -222 |
| Mar 2024 | 263 | -191 | 72 |
OCF/PAT (latest FY) 1.41 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
- 2026-08-06 — RESULT_ANNOUNCEMENT: Financial Results
📄 Latest Filings Snapshot
- P&L: Sales: 2,250 Cr (YoY +2.6%); NetProfit: 362 Cr (YoY +3.7%); EPS: 17.12
- Quarterly: Sales last 3Q: 556, 602, 554 Cr; Net Profit last 3Q: 100, 104, 73 Cr
- Ratios: P/E: 84.0; ROCE: 19.6; ROE: 15.4; Div Yield: 0.00; Book Value: 117; Mkt Cap: 30,895
- Investors: Promoters 34.53% | FII 19.65% | DII 32.71% | Public 13.11%
Why selected: VCP-confirmed Stage 2 (vcp=85, inv=95.2) in top-ranked sector Metals & Mining (strength=83) · The confidence in growth is balanced with the elevated valuation metrics and market conditions.
LAURUSLABS · Pharma & Healthcare · Pharma APIs & Formulations
B What the company does
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,871 · ₹1,555 · ₹1,457
Pivots — PP ₹1,842 · R1 ₹1,894 · R2 ₹1,921 · S1 ₹1,814 · S2 ₹1,762
💡 Thesis
Laurus Labs shows a robust technical setup with an RSI of 68.1 and an efficient EMA structure indicative of strong bullish momentum. The latest quarterly revenue is impressive at ₹2,026 Cr, with a YoY growth rate of 29.04% and a PAT of ₹362 Cr, marking a staggering 123.46% YoY increase, demonstrating significant operational efficiency and earnings potential.
📈 Technical View
Technicals indicate a strong bullish trend, with the price approaching its 52-week high (-0.25%). The recent returns reflect strong momentum with 83.49% growth over six months. The timeframe over EMA's supports strong price action and reliability.
🏦 Fundamental View
With a solid OCF to PAT ratio of 1.49 and robust PAT CAGR of 8.30% over the last four years, Laurus Labs displays a healthy ability to convert earnings into cash. The recent reduction in net debt to ₹2,209 Cr suggests improved financial stability.
🧭 Sector View
With the Pharma & Healthcare sector exhibiting high strength (83.34), Laurus stands out as a market leader in its niche, indicated by its RS of 93.91%, reflecting superior performance versus peers.
💰 Valuation
Currently trading at a P/E of 92.5, suggesting valuation might be high relative to traditional earnings metrics compared to lower multiples within the sector.
🚀 Key Catalysts
- Revenue of ₹2,026 Cr in the latest quarter with OPM at 32%
- Strong EPS growth of 20.24 driven by PAT growth
- Institutional backing of 76% fostering confidence
⚠️ Key Risks
- Major dependency on regulatory approvals in pharma
- Market volatility impacting stock valuation
- Fluctuating input costs affecting margins
🎯 Action
Consider entering near ₹1,800, focusing on pullback levels.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹EPS × 20x peer median = median; ±20% for bull/bear.
- Strong revenue growth at 29.4% YoY
- Solid earnings quality reflecting operational maturity
- Innovative pipeline enhancing market position
- Valuation concerns highlighted by a high P/E
- Potential for slowdown in pharma demand
- Risk from regulatory changes impacting operations
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: The analyst consensus likely remains optimistic regarding Laurus Labs, focusing on its superior earnings growth and strong revenue pipeline against the backdrop of industry dynamics. However, brokers might flag high valuation as a concern in context with peers.
T Technicals
| Closei | ₹1866.20 (2026-08-25) |
| EMA 20/50/200i | ₹1789.90 / ₹1663.04 / ₹1297.53 |
| EMA50 slope (20d)i | 13.46% |
| RSI(14)i | 68.10 |
| ATR(14)i | ₹37.42 (2.01%) |
| 52W High / Lowi | ₹1870.80 / ₹823.10 |
| From 52W highi | -0.2% |
| Returns 1M/3M/6M/1Yi | 8.9% / 35.1% / 83.5% / 109.7% |
| Vol vs 20d avgi | 1.90x |
F Fundamental Scores
| Piotroski F-scorei | 5 / 6 (approx) |
| Altman Z-scorei | 2.20 (Z′ approx) |
| Beneish M-scorei | -2.68 (low, simplified) |
| Forensic riski | low (derived) |
| ROE / ROCEi | 20.6% (computed) / 20.5% (computed) |
| Revenue growth (3Y)i | 4.7% (4Y CAGR) |
| PAT growth (3Y)i | 8.3% (4Y CAGR) |
| Debt / Equityi | 0.48 (computed) |
| Promoter holdingi | 27.5% |
| FII / DII holdingi | 28.0% / 13.7% |
| NPMi | 15.0% (computed) |
| EPSi | 20.24 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,866.2 |
| EPS (TTM proxy)i | 20.24 |
| P/E (Screener ratios) | 92.5x |
| Market cap (Screener) | ₹101,100 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹98.2 |
| Dividend yield | 0.1% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | ₹2,209 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Pharma & Healthcare
- Sub-sector: Pharma APIs & Formulations
- Sector strength: 83.34
- Peer avg RS: 92.9% · Avg tech: 83.34 · Avg fund: 79.14
- Sector universe: 26 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹1,790 – ₹1,866 |
| Stop loss | ₹1,613 |
| Target 2M | ₹1,978 |
| Target 4M | ₹2,058 |
| Target 6M | ₹2,140 |
| Reward / Risk (4M) | 0.76× |
| Reward / Risk (6M) | 1.08× |
| Risk per share | ₹253 |
| Extension | EXTENDED - 12.2% above EMA50; RSI 68; -0.2% from 52w high |
| Suggested position size | 4% of portfolio |
Risk score breakdown: ATR 2.0% (+0.5) · Near high -0.2% (+1.0) · Extended (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 2026 | 32 | 362 | 6.80 |
| Mar 2026 | 1812 | 28 | 282 | 5.17 |
| Dec 2025 | 1778 | 27 | 252 | 4.66 |
| Sep 2025 | 1653 | 24 | 194 | 3.61 |
Rev QoQ +11.8% · YoY +29.0% · PAT QoQ +28.4% · YoY +123.5% · OPM vs 4Q avg +750 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 7270 | 28 | 1091 | 20.24 |
| Mar 2026 | 6813 | 26 | 890 | 16.46 |
| Mar 2025 | 5554 | 19 | 358 | 6.64 |
| Mar 2024 | 5041 | 15 | 162 | 2.98 |
| Mar 2023 | 6041 | 26 | 793 | 14.67 |
4Y CAGR — Revenue 4.7% · PAT 8.3% · EPS 8.4%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 2518 | 2209 | 10511 |
| Mar 2025 | 2764 | 2531 | 9336 |
| Mar 2024 | 2577 | 2453 | 8387 |
Debt trend falling
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 1624 | -1086 | 538 |
| Mar 2025 | 602 | -680 | -78 |
| Mar 2024 | 666 | -822 | -156 |
OCF/PAT (latest FY) 1.49 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 7,270 Cr (YoY +6.7%); NetProfit: 1,091 Cr (YoY +22.6%); EPS: 20.24
- Quarterly: Sales last 3Q: 1,778, 1,812, 2,026 Cr; Net Profit last 3Q: 252, 282, 362 Cr
- Ratios: P/E: 92.5; ROCE: 17.8; ROE: 18.3; Div Yield: 0.11; Book Value: 98.2; Mkt Cap: 1,01,100
- Investors: Promoters 27.47% | FII 28.00% | DII 13.73% | Public 30.79%
Why selected: VCP-confirmed Stage 2 (vcp=83, inv=96.0) in top-ranked sector Pharma & Healthcare (strength=73) · Reasonable conviction given solid growth indicators but tempered by the high valuation.
GNA · EV & Auto Ancillaries · Auto Ancillaries
B What the company does
GNA Axles is engaged in the Business of manufacturing auto components for the four-wheeler industry, primary product being Rear Axles, Shafts, Spindles & other Automobiles Components for sale in domestic and foreign market.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹602 · ₹592 · ₹563
Pivots — PP ₹560 · R1 ₹573 · R2 ₹598 · S1 ₹535 · S2 ₹522
💡 Thesis
GNA Axles showcases solid technical momentum with an RSI of 54.87, indicating a bullish phase as the stock remains in Stage 2. The firm's revenue growth of 36.63% YoY reflects positive demand trends in the auto ancillary sector. The PAT growth at 65.22% YoY underlines the improving operational efficiency within this cyclical landscape.
📈 Technical View
Technical indicators show the company at a pivotal moment, trading roughly 8.78% from its 52-week high. The stock's trajectory has remained strong with returns of approximately 69.96% over the past year. It displays a well-structured EMA stack and an increasing upward slope.
🏦 Fundamental View
The company's revenue for the TTM stands at ₹1,605 Cr with a PAT of ₹132 Cr, while the OCF to PAT ratio is notably high at 1.62, reflecting strong cash generation. The balanced balance sheet with stable debt levels reveals a calculated approach in financing.
🧭 Sector View
Positioned in the EV & Auto Ancillaries sector with a strength of 74.66, GNA ranks favorably among peers with strong momentum evident in its technical performance.
💰 Valuation
Trading at a P/E of 17.8 signifies undervaluation concerning its growth potential compared to much higher multiples within its sector.
🚀 Key Catalysts
- Latest quarterly revenue of ₹470 Cr with OPM improvement to 15%
- Substantial PAT of ₹38 Cr, marking a 65% YoY increase
- Strong promoter holding at 65.78% demonstrating insider confidence
⚠️ Key Risks
- Industry cyclical downturn affecting performance
- Raw material price fluctuations impacting costs
- Market sentiment volatility impacting stock valuation
🎯 Action
Consider adding to positions above ₹550 for broad exposure, maintain stop-loss.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹EPS × 20x peer median = median; ±20% for bull/bear.
- Strong demand growth reflected in revenue trends
- Effective cost management improving margins
- Leading market position with robust promoter support
- Cyclical risks affecting revenue stability
- Valuation concerns based on recent price surge
- Dependence on the volatility of raw material costs
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Consensus among analysts is likely positive, reflecting strong growth prospects and healthy financial metrics. Brokers may emphasize the steady operational growth and stable financial foundations but could also caution about sector cyclicality risks.
T Technicals
| Closei | ₹548.80 (2026-08-25) |
| EMA 20/50/200i | ₹544.76 / ₹508.09 / ₹417.00 |
| EMA50 slope (20d)i | 10.67% |
| RSI(14)i | 54.87 |
| ATR(14)i | ₹21.41 (3.90%) |
| 52W High / Lowi | ₹601.65 / ₹291.80 |
| From 52W highi | -8.8% |
| Returns 1M/3M/6M/1Yi | 7.2% / 43.5% / 32.4% / 70.0% |
| Vol vs 20d avgi | 0.37x |
F Fundamental Scores
| Piotroski F-scorei | 5 / 6 (approx) |
| Altman Z-scorei | 3.17 (Z′ approx) |
| Beneish M-scorei | -2.66 (low, simplified) |
| Forensic riski | low (derived) |
| ROE / ROCEi | 13.1% (computed) / 15.6% (computed) |
| Revenue growth (3Y)i | 0.3% (4Y CAGR) |
| PAT growth (3Y)i | 0.4% (4Y CAGR) |
| Debt / Equityi | 0.22 (computed) |
| Promoter holdingi | 65.8% |
| FII / DII holdingi | 1.7% / 11.6% |
| NPMi | 8.2% (computed) |
| EPSi | 30.80 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹548.8 |
| EPS (TTM proxy)i | 30.80 |
| P/E (Screener ratios) | 17.8x |
| Market cap (Screener) | ₹2,360 Cr |
| Market-cap bucketi | MID_CAP |
| Book value | ₹234.0 |
| Dividend yield | 0.6% |
| Sales (latest)i | — |
| PAT (latest)i | ₹132 Cr (12.8% YoY) |
| Net debt (3Y)i | ₹218 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: EV & Auto Ancillaries
- Sub-sector: Auto Ancillaries
- Sector strength: 74.66
- Peer avg RS: 85.7% · Avg tech: 74.66 · Avg fund: 76.54
- Sector universe: 21 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹538 – ₹549 |
| Stop loss | ₹493 |
| Target 2M | ₹613 |
| Target 4M | ₹656 |
| Target 6M | ₹699 |
| Reward / Risk (4M) | 1.91× |
| Reward / Risk (6M) | 2.68× |
| Risk per share | ₹56 |
| Extension | NORMAL |
| Suggested position size | 8% of portfolio |
Risk score breakdown: ATR 3.9% (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 470 | 15 | 38 | 8.91 |
| Mar 2026 | 411 | 14 | 31 | 7.18 |
| Dec 2025 | 375 | 18 | 32 | 7.44 |
| Sep 2025 | 348 | 18 | 31 | 7.27 |
Rev QoQ +14.4% · YoY +36.6% · PAT QoQ +22.6% · YoY +65.2% · OPM vs 4Q avg -33 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 1605 | 16 | 132 | 30.80 |
| Mar 2026 | 1478 | 16 | 117 | 27.24 |
| Mar 2025 | 1540 | 14 | 107 | 24.94 |
| Mar 2024 | 1506 | 13 | 100 | 23.28 |
| Mar 2023 | 1583 | 15 | 130 | 30.35 |
4Y CAGR — Revenue 0.3% · PAT 0.4% · EPS 0.4%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 218 | 218 | 1520 |
| Mar 2025 | 259 | 259 | 1365 |
| Mar 2024 | 213 | 213 | 1219 |
Debt trend stable
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 214 | -155 | 59 |
| Mar 2025 | 92 | -111 | -19 |
| Mar 2024 | 98 | -86 | 12 |
OCF/PAT (latest FY) 1.62 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 1,605 Cr (YoY +8.6%); NetProfit: 132 Cr (YoY +12.8%); EPS: 30.80
- Quarterly: Sales last 3Q: 375, 411, 470 Cr; Net Profit last 3Q: 32, 31, 38 Cr
- Ratios: P/E: 17.8; ROCE: 14.3; ROE: 12.2; Div Yield: 0.55; Book Value: 234; Mkt Cap: 2,360
- Investors: Promoters 65.78% | FII 1.70% | DII 11.59% | Public 20.94%
Why selected: VCP-confirmed Stage 2 (vcp=80, inv=97.1) in top-ranked sector EV & Auto Ancillaries (strength=65) · Strong confidence charged by robust growth metrics and favorable term structures.
UNIPARTS · Capital Goods & Industrials · Industrial Products
B What the company does
Incorporatedin1994, Uniparts India provides engineering systems and solutions catering to international OEMs across the off-highway vehicle, agricultural machinery, and construction equipment sectors [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹839 · ₹723 · ₹706
Pivots — PP ₹824 · R1 ₹847 · R2 ₹868 · S1 ₹802 · S2 ₹779
💡 Thesis
Uniparts India is positioned well within the Capital Goods & Industrials sector, evidenced by its technical strength with an RSI of 64.15 and a favorable distance from its 52-week high at -2.28%. The stock shows strong P&L trends with a YoY revenue growth of 26.64% and a PAT QoQ increase of 11.76%. The company boasts a solid cash-flow profile, with an OCF/PAT ratio of 0.967, indicating quality earnings. With a low debt-to-equity ratio of 0.178 and rising equity at ₹870 Cr, it showcases financial resilience amidst a stable operational environment.
📈 Technical View
The stock is currently in a bullish trend, supported by an EMA stack where the EMA20 is above EMA50 and EMA200, affirming momentum. It has retraced only slightly at -2.28% from the 52-week high, denoting a healthy uptrend. Volume is in line with its 20-day average as indicated, which further supports the ongoing technical strength.
🏦 Fundamental View
Uniparts has demonstrated robust operational efficiency, with an operating margin (OPM) percentage increase of 400 bps YoY from 20% to 24%. The balance sheet shows significant strength, with total assets of ₹1,255 Cr and net debt being negative at ₹50 Cr, thereby providing a safe cushion against financial distress. Earnings quality is high with an EPS CAGR reported at 9.89%.
🧭 Sector View
The Capital Goods & Industrials sector exhibits a substantial strength score of 74.52, with Uniparts outperforming at a relative strength of 94.03% against the broader Nifty 500. It ranks favorably among its peers with a superior technical score of 96.72.
💰 Valuation
The stock trades at a P/E ratio of 20.4, which appears justified given its growth rates and sector-specific strength.
🚀 Key Catalysts
- Latest quarterly revenue at ₹347 Cr, reflecting a 2.36% QoQ rise
- PAT growth of 67.65% YoY
- Institutional holding at 73.5%, indicating market confidence
⚠️ Key Risks
- Cyclical downturn risks inherent to the Capital Goods sector
- Potential for operational disruptions amid rising input costs
- Earnings volatility due to reliance on few major OEM contracts
🎯 Action
Consider entering at around ₹800-810 with a tight stop-loss at ₹708, watching for any pullbacks.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹39.98 EPS × 23 = ₹928 median; ±20% for bull/bear scenarios.
- Strong earnings momentum with 67.65% PAT growth
- Positive cash flow generation and solid balance sheet
- High institutional ownership fostering investor confidence
- Cyclical risks given the industrial exposure
- Concerns about valuation relative to peer companies
- Rising debt influencing long-term financial health
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Consensus among analysts may lean towards a 'BUY' given the stock's strong fundamentals and recent earnings momentum. Concerns may revolve around its market positioning and valuation metrics, but the positive earnings revisions trend and high private institutional backing align with a bullish outlook. This is a synthesised consensus read without direct broker input.
T Technicals
| Closei | ₹825.60 (2026-08-25) |
| EMA 20/50/200i | ₹788.94 / ₹729.90 / ₹584.91 |
| EMA50 slope (20d)i | 13.08% |
| RSI(14)i | 64.15 |
| ATR(14)i | ₹29.41 (3.56%) |
| 52W High / Lowi | ₹844.90 / ₹391.80 |
| From 52W highi | -2.3% |
| Returns 1M/3M/6M/1Yi | 17.1% / 35.3% / 70.8% / 95.1% |
| Vol vs 20d avgi | 0.95x |
F Fundamental Scores
| Piotroski F-scorei | 3 / 6 (approx) |
| Altman Z-scorei | 3.52 (Z′ approx) |
| Beneish M-scorei | -2.51 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 20.7% (computed) / 24.2% (computed) |
| Revenue growth (3Y)i | -2.3% (4Y CAGR) |
| PAT growth (3Y)i | -3.2% (4Y CAGR) |
| Debt / Equityi | 0.18 (computed) |
| Promoter holdingi | 65.9% |
| FII / DII holdingi | 3.4% / 4.9% |
| NPMi | 14.5% (computed) |
| EPSi | 39.98 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹825.6 |
| EPS (TTM proxy)i | 39.98 |
| P/E (Screener ratios) | 20.4x |
| Market cap (Screener) | ₹3,729 Cr |
| Market-cap bucketi | MID_CAP |
| Book value | ₹193.0 |
| Dividend yield | 1.9% |
| Sales (latest)i | — |
| PAT (latest)i | ₹180 Cr (13.9% YoY) |
| Net debt (3Y)i | ₹-50 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Capital Goods & Industrials
- Sub-sector: Industrial Products
- Sector strength: 74.52
- Peer avg RS: 93.6% · Avg tech: 74.52 · Avg fund: 77.66
- Sector universe: 13 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹789 – ₹826 |
| Stop loss | ₹708 |
| Target 2M | ₹914 |
| Target 4M | ₹973 |
| Target 6M | ₹1,032 |
| Reward / Risk (4M) | 1.25× |
| Reward / Risk (6M) | 1.75× |
| Risk per share | ₹118 |
| Extension | EXTENDED - 13.1% above EMA50; -2.3% from 52w high; 1M return +17.1% |
| Suggested position size | 5% of portfolio |
Risk score breakdown: ATR 3.6% (+1.5) · Near high -2.3% (+1.0) · Extended (+1.0) · Debt rising (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 347 | 24 | 57 | 12.54 |
| Mar 2026 | 339 | 24 | 51 | 11.33 |
| Dec 2025 | 281 | 20 | 33 | 7.38 |
| Sep 2025 | 277 | 21 | 39 | 8.73 |
Rev QoQ +2.4% · YoY +26.6% · PAT QoQ +11.8% · YoY +67.6% · OPM vs 4Q avg +517 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 1244 | 22 | 180 | 39.98 |
| Mar 2026 | 1170 | 21 | 158 | 35.07 |
| Mar 2025 | 964 | 15 | 88 | 19.50 |
| Mar 2024 | 1140 | 18 | 125 | 27.63 |
| Mar 2023 | 1366 | 22 | 205 | 45.40 |
4Y CAGR — Revenue -2.3% · PAT -3.2% · EPS -3.1%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 155 | -50 | 1255 |
| Mar 2025 | 120 | -125 | 1176 |
| Mar 2024 | 103 | -53 | 1140 |
Debt trend rising · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 174 | 20 | 194 |
| Mar 2025 | 182 | -106 | 76 |
| Mar 2024 | 200 | -160 | 40 |
OCF/PAT (latest FY) 0.97 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
- 2026-08-04 — RESULT_ANNOUNCEMENT: Financial Results/Dividend
📄 Latest Filings Snapshot
- P&L: Sales: 1,244 Cr (YoY +6.3%); NetProfit: 180 Cr (YoY +13.9%); EPS: 39.98
- Quarterly: Sales last 3Q: 281, 339, 347 Cr; Net Profit last 3Q: 33, 51, 57 Cr
- Ratios: P/E: 20.4; ROCE: 21.6; ROE: 18.3; Div Yield: 1.85; Book Value: 193; Mkt Cap: 3,729
- Investors: Promoters 65.87% | FII 3.38% | DII 4.94% | Public 25.71%
Why selected: Stage 2 leader in top sector Capital Goods & Industrials (strength=80), inv=95.9 · While the fundamentals appear robust, current market conditions and cyclical industry concerns warrant a balanced approach.
CUPID · Pharma & Healthcare · Medical Devices & Sexual Wellness
B What the company does
Established in 1993, CUPID Limited is India's premier manufacturer of male and female condoms, personal lubricant, and IVD kits. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹299 · ₹226 · ₹134
Pivots — PP ₹284 · R1 ₹290 · R2 ₹298 · S1 ₹275 · S2 ₹269
💡 Thesis
CUPID Ltd, operating within the Pharma & Healthcare sector, showcases strong technicals with an RSI of 64.99 and upward momentum marked by an EMA structure where EMA20 is above both EMA50 and EMA200. Its recent revenue growth of 158.33% YoY and a quarterly PAT increase of 22.22% signal robust demand for its products. The company exhibits excellent operational leverage with a high OPM at 39% and futuristic EPS growth projected at 46.74% CAGR.
📈 Technical View
The technical outlook is highly favorable, showcasing an ongoing bullish trend with significant momentum reflected in the strong return of 233.17% over the past year. Volume remains below average but supportive of price action, and any additional uptick in activity should further bolster breakout confidence.
🏦 Fundamental View
The latest quarterly performance shows a remarkable OPM of 39% and PAT at ₹44 Cr, reinforcing the company's solid earnings capacity. CUPID has managed to grow its revenue effectively despite a challenging market, showing a net equity of ₹450 Cr with a stable debt level, resulting in a decreasing debt-to-equity ratio.
🧭 Sector View
CUPID thrives in a strong Pharma sector context with a peer relative strength of 99.88%, pointing to its solid competitive positioning. The strong sector average fundamental and technical scores reinforce CUPID's favorable standing.
💰 Valuation
Despite the high growth metrics, the valuation appears stretched with a P/E ratio of 276; current trading levels suggest caution regarding prospective returns.
🚀 Key Catalysts
- Recent quarter showing revenue of ₹155 Cr, a QoQ growth of 29.17%
- Robust PAT growth of 193.33% YoY indicating strong demand
- Sector strength at 83.34% enhancing growth prospects
⚠️ Key Risks
- Heightened competition from new entrants in the health product market
- Regulatory scrutiny on health product categories could lead to operational shifts
- Volatility in commodity prices affecting manufacturing costs
🎯 Action
Enter at current levels of ₹281-285, keeping a stop-loss at ₹223, being cautious of market pullbacks.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹1.02 EPS × 320 = ₹325 median; ±20% for bull/bear cases.
- Strong recent revenue growth trend substantiated by orders
- Premier market position in a growing sector
- Improving operational metrics including high OPM
- Significantly high valuation metrics limiting upside
- Volatility associated with consumer health-related sectors
- Potential legislative pressures on product categories
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analysts generally view CUPID as a strong growth candidate, highlighting its revenue momentum and competitive market positioning. There are concerns about its high P/E and potential volatility given the rapid price increases. Recent estimate revisions have aligned positively with growing market recognition of its brand strength. This is a synthesised consensus read without direct broker input.
T Technicals
| Closei | ₹281.76 (2026-08-25) |
| EMA 20/50/200i | ₹266.53 / ₹230.36 / ₹141.61 |
| EMA50 slope (20d)i | 27.29% |
| RSI(14)i | 64.99 |
| ATR(14)i | ₹16.63 (5.90%) |
| 52W High / Lowi | ₹299.00 / ₹32.87 |
| From 52W highi | -5.8% |
| Returns 1M/3M/6M/1Yi | 27.2% / 118.6% / 233.2% / 722.2% |
| Vol vs 20d avgi | 0.34x |
F Fundamental Scores
| Piotroski F-scorei | 2 / 6 (approx) |
| Altman Z-scorei | 4.69 (Z′ approx) |
| Beneish M-scorei | -1.93 (watch, simplified) |
| Forensic riski | high (derived) |
| ROE / ROCEi | 30.4% (computed) / 36.8% (computed) |
| Revenue growth (3Y)i | 32.0% (4Y CAGR) |
| PAT growth (3Y)i | 47.4% (4Y CAGR) |
| Debt / Equityi | 0.12 (computed) |
| Promoter holdingi | 46.2% |
| FII / DII holdingi | 4.2% / 0.3% |
| NPMi | 30.2% (computed) |
| EPSi | 1.02 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹281.8 |
| EPS (TTM proxy)i | 1.02 |
| P/E (Screener ratios) | 276.0x |
| Market cap (Screener) | ₹37,915 Cr |
| Market-cap bucketi | SMALL_CAP |
| Book value | ₹3.4 |
| Dividend yield | 0.0% |
| Sales (latest)i | ₹453 Cr (26.5% YoY) |
| PAT (latest)i | ₹137 Cr (26.9% YoY) |
| Net debt (3Y)i | ₹-19 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Pharma & Healthcare
- Sub-sector: Medical Devices & Sexual Wellness
- Sector strength: 83.34
- Peer avg RS: 92.9% · Avg tech: 83.34 · Avg fund: 79.14
- Sector universe: 26 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹267 – ₹282 |
| Stop loss | ₹223 |
| Target 2M | ₹332 |
| Target 4M | ₹365 |
| Target 6M | ₹420 |
| Reward / Risk (4M) | 1.43× |
| Reward / Risk (6M) | 2.36× |
| Risk per share | ₹58 |
| Extension | OVEREXTENDED - 5.7% above EMA20; 22.3% above EMA50; 1M return +27.2% |
| Suggested position size | 3% of portfolio |
Risk score breakdown: ATR 5.9% (+2.5) · Overextended (+2.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 155 | 39 | 44 | 0.33 |
| Mar 2026 | 120 | 31 | 36 | 0.27 |
| Dec 2025 | 94 | 37 | 33 | 0.24 |
| Sep 2025 | 84 | 34 | 24 | 0.18 |
Rev QoQ +29.2% · YoY +158.3% · PAT QoQ +22.2% · YoY +193.3% · OPM vs 4Q avg +917 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 453 | 35 | 137 | 1.02 |
| Mar 2026 | 358 | 33 | 108 | 0.80 |
| Mar 2025 | 183 | 23 | 41 | 0.30 |
| Mar 2024 | 172 | 30 | 40 | 0.30 |
| Mar 2021 | 149 | 28 | 29 | 0.22 |
4Y CAGR — Revenue 32.0% · PAT 47.4% · EPS 46.7%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 56 | -19 | 553 |
| Mar 2025 | 19 | -84 | 372 |
| Mar 2024 | 12 | -135 | 320 |
Debt trend stable · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 46 | 28 | 74 |
| Mar 2025 | -11 | 45 | 34 |
| Mar 2024 | 8 | -80 | -72 |
OCF/PAT (latest FY) 0.34 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 453 Cr (YoY +26.5%); NetProfit: 137 Cr (YoY +26.9%); EPS: 1.02
- Quarterly: Sales last 3Q: 94, 120, 155 Cr; Net Profit last 3Q: 33, 36, 44 Cr
- Ratios: P/E: 276; ROCE: 33.5; ROE: 27.3; Div Yield: 0.00; Book Value: 3.35; Mkt Cap: 37,915
- Investors: Promoters 46.24% | FII 4.17% | DII 0.34% | Public 49.23%
Why selected: Stage 2 leader in top sector Pharma & Healthcare (strength=73), inv=97.8 · Strong growth potential exists; however, high valuation warrants balanced exposure.
AETHER · Chemicals & Petrochemicals · Unmapped
B What the company does
Incorporated in 2013, Aether Industries Limited is a manufacturer of specialty chemicals. The company is sole Indian manufacturer for chemicals such as 4-(2-Methoxyethyl) Phenol (4MEP), and 3-Methoxy-2-Methylbenzoyl Chloride (MMBC), Thiophene-2-Ethanol (T2E), Ortho Tolyl Benzo Nitrile (OTBN), N-Octyl-D-Glucamine, Delta-Valerolactone, and Bifenthrin Alcohol. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,692 · ₹1,538 · ₹1,275
Pivots — PP ₹1,634 · R1 ₹1,684 · R2 ₹1,733 · S1 ₹1,584 · S2 ₹1,535
💡 Thesis
Aether Industries stands at a strong technical inflection with an RSI of 61.66 and trading favorably within its EMA structure, particularly above EMA50 and EMA200, suggesting continued upward momentum. The company recorded a revenue of ₹327 Cr in the last quarter, delivering a QoQ increase of 7.21% and a robust annual revenue growth reflected in its 17.27% CAGR. Furthermore, with an operating margin of 31% and a solid EPS of ₹17.73, it presents an appealing profile for growth investors.
📈 Technical View
The stock has a favorable trajectory with a consistent higher highs and higher lows pattern, indicating a solid bullish trend. Current prices are within 3.43% of the 52-week high but remain above the key EMA thresholds which are acting in support.
🏦 Fundamental View
The company’s financial metrics are supportive, with net equity at ₹2,456 Cr and a rise in borrowings to ₹458 Cr illustrating manageable leverage. However, cash flow remains a concern with negative FCF, which signals a need for attention. OCF has improved, reflected in a positive relationship to PAT at approximately 0.6.
🧭 Sector View
While the Chemicals & Petrochemicals sector shows varying strengths, Aether's upward movement signals positive alignment with broader sector trends, ranking relatively favorably despite lacking explicit comparative metrics.
💰 Valuation
Valuation appears spread given a P/E ratio of 90.4, implying substantial stretch relative to earnings growth metrics.
🚀 Key Catalysts
- Quarterly revenue recognized at ₹327 Cr, showing steady growth
- Significant institutional ownership at 78.5%, showing confidence from larger investors
- Sector strength trends in alignment with emerging chemical products
⚠️ Key Risks
- Increased raw material costs impacting profitability
- Competition within the specialty chemicals sector could pressure margins
- Liquidity risks stemming from negative cash flow positions
🎯 Action
Watch for a potential entry around ₹1,600-1,620 with a stop-loss set at ₹1,432, ideally establishing positions at that range.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹17.73 EPS × 101 = ₹1,800 median; ±20% for potential variability.
- Strong growth trajectory in specialty chemicals
- Growing market adoption for its innovative products
- Positive long-term sector outlook in chemicals
- High leverage and recent rising debt metrics raise concerns
- Volatile cash flow posing risks to ongoing operations
- Challenges in maintaining margins under cost pressures
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analysts likely regard Aether favorably due to its solid financial performance, but caution may arise from high P/E valuations and negative cash flow perspectives. The consensus remains bullish on this growth story, emphasizing strong sales although questions persist over sustainability. This is a synthesised consensus read without direct broker input.
T Technicals
| Closei | ₹1633.90 (2026-08-25) |
| EMA 20/50/200i | ₹1588.48 / ₹1475.86 / ₹1158.96 |
| EMA50 slope (20d)i | 11.79% |
| RSI(14)i | 61.66 |
| ATR(14)i | ₹51.61 (3.16%) |
| 52W High / Lowi | ₹1692.00 / ₹726.45 |
| From 52W highi | -3.4% |
| Returns 1M/3M/6M/1Yi | 10.4% / 49.3% / 68.7% / 112.4% |
| Vol vs 20d avgi | 0.55x |
F Fundamental Scores
| Piotroski F-scorei | 2 / 6 (approx) |
| Altman Z-scorei | 3.15 (Z′ approx) |
| Beneish M-scorei | -2.46 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 9.6% (computed) / 11.4% (computed) |
| Revenue growth (3Y)i | 17.3% (4Y CAGR) |
| PAT growth (3Y)i | 16.0% (4Y CAGR) |
| Debt / Equityi | 0.19 (computed) |
| Promoter holdingi | 74.9% |
| FII / DII holdingi | 7.4% / 10.5% |
| NPMi | 19.1% (computed) |
| EPSi | 17.73 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,633.9 |
| EPS (TTM proxy)i | 17.73 |
| P/E (Screener ratios) | 90.4x |
| P/E (derived price ÷ EPS) | 92.2x |
| Market cap (Screener) | ₹21,690 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹185.0 |
| Dividend yield | 0.0% |
| Sales (latest)i | — |
| PAT (latest)i | ₹235 Cr (7.3% YoY) |
| Net debt (3Y)i | ₹458 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
No sector aggregate.
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹1,588 – ₹1,634 |
| Stop loss | ₹1,432 |
| Target 2M | ₹1,789 |
| Target 4M | ₹1,892 |
| Target 6M | ₹2,043 |
| Reward / Risk (4M) | 1.28× |
| Reward / Risk (6M) | 2.02× |
| Risk per share | ₹202 |
| Extension | NORMAL |
| Suggested position size | 8% of portfolio |
Risk score breakdown: ATR 3.2% (+1.5) · Debt rising (+1.0) · OCF/PAT watch (+0.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 327 | 31 | 63 | 4.73 |
| Mar 2026 | 305 | 27 | 54 | 4.07 |
| Dec 2025 | 319 | 35 | 64 | 4.86 |
| Sep 2025 | 280 | 31 | 54 | 4.07 |
Rev QoQ +7.2% · YoY +27.2% · PAT QoQ +16.7% · YoY +34.0% · OPM vs 4Q avg -17 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 1231 | 31 | 235 | 17.73 |
| Mar 2026 | 1160 | 31 | 219 | 16.54 |
| Mar 2025 | 841 | 29 | 158 | 11.95 |
| Mar 2024 | 598 | 22 | 82 | 6.22 |
| Mar 2023 | 651 | 29 | 130 | 10.47 |
4Y CAGR — Revenue 17.3% · PAT 16.0% · EPS 14.1%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 458 | 458 | 3201 |
| Mar 2025 | 200 | 200 | 2644 |
| Mar 2024 | 183 | 183 | 2401 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 142 | -619 | -477 |
| Mar 2025 | 100 | -418 | -318 |
| Mar 2024 | -16 | -424 | -440 |
OCF/PAT (latest FY) 0.60 → earnings quality: WATCH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 1,231 Cr (YoY +6.1%); NetProfit: 235 Cr (YoY +7.3%); EPS: 17.73
- Quarterly: Sales last 3Q: 319, 305, 327 Cr; Net Profit last 3Q: 64, 54, 63 Cr
- Ratios: P/E: 90.4; ROCE: 11.9; ROE: 9.66; Div Yield: 0.00; Book Value: 185; Mkt Cap: 21,690
- Investors: Promoters 74.92% | FII 7.42% | DII 10.49% | Public 7.17%
Why selected: VCP-confirmed Stage 2 (vcp=82, inv=97.7); sector Chemicals & Petrochemicals not in current top-10 rotation · While strong growth indicators exist, cash flow issues introduce risk, requiring vigilant management.
RADICO · FMCG & Consumer Goods · Unmapped
B What the company does
Incorporated in the year 1943, Radico Khaitan is one of the most recognised IMFL (Indian Made Foreign Liquor) brands in India. [1] The company was initially known as Rampur Distillery Company and was focussed on distillation and bottling for branded players and canteen stores of armed forces. Later on in the year 1997, Radico Khaitan ventured into its own branded IMFL products and launched its first brand 8PM whisky which became its millionarie brand within a year of its launch. [2]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹4,590 · ₹4,162 · ₹3,679
Pivots — PP ₹4,646 · R1 ₹4,731 · R2 ₹4,831 · S1 ₹4,546 · S2 ₹4,461
💡 Thesis
Radico Khaitan exhibits solid growth potential, demonstrated by a revenue YoY increase of 11.82% and a PAT growth of 75.57%, alongside stable operating margins improving by 516 bps to 21% in the latest quarter. With a current RSI of 64.60, the stock is positioned within a bullish phase and shows strong price momentum with an RS of 91.36% against Nifty 500. Coupled with a robust ROCE of 24.2%, there is significant upside potential in a favorable sector context.
📈 Technical View
The stock is in a bullish setup with key technical indicators supporting upward momentum, notably with EMA20, EMA50, and EMA200 all trending positively. Price is only 2.46% away from the 52-week high, confirming its upward trajectory amidst a rising wedge pattern, warranting close observation for potential breakout points.
🏦 Fundamental View
The latest quarter's revenue reached ₹1684 Cr, with a PAT of ₹230 Cr marking a notable QoQ increase of 28.49%. The balance sheet shows decreasing debt from ₹750 Cr to ₹498 Cr, improving the net debt to equity ratio to 0.15, while the OCF/PAT ratio stands at a strong 1.06, indicating high earnings quality.
🧭 Sector View
Radico Khaitan benefits from a sector strength score of 71.62, outperforming its peers with a relative strength percentage of 91.36%. This places the company favorably within the FMCG & Consumer Goods sector amidst strong demand trends.
💰 Valuation
The current P/E ratio of 87.2 indicates a stretched valuation, especially given EPS projected growth rates; however, earnings momentum might justify this premium in a bullish phase.
🚀 Key Catalysts
- Strong quarterly PAT growth of 75.57%
- Improving operating profit margins (~21%)
- Sector strength score of 71.62
⚠️ Key Risks
- Valuation pressure with PEG of 2.59 indicating potential risk
- Market saturation with increasing competition within the FMCG space
- Dependence on government regulations affecting liquor industry
🎯 Action
Enter at current levels around ₹4630, with a stop-loss set at ₹4113 based on EMA50 placement.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹EPS × 22x peer multiple = ₹5200 median; ±20% for target range
- Strong earnings momentum evident in quarterly results
- Robust cash flow with OCF/PAT above 1
- Sector-leading ROCE supporting growth
- High P/E ratio suggesting potential valuation risk
- Concerns over market saturation in the FMCG sector
- Debt levels still a concern in relation to cash flows
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: The synthesised consensus view among analysts leans towards a bullish stance given Radico's strong revenue and PAT growth. Analysts would likely highlight the company's ability to expand market share while mitigating risks through improved operational efficiencies. There may be concerns regarding valuation at these multiples but potential earnings growth mitigates this worry. Note this consensus is a synthesis, with no live broker feedback incorporated.
T Technicals
| Closei | ₹4630.00 (2026-08-25) |
| EMA 20/50/200i | ₹4532.54 / ₹4240.96 / ₹3544.23 |
| EMA50 slope (20d)i | 10.86% |
| RSI(14)i | 64.60 |
| ATR(14)i | ₹96.27 (2.08%) |
| 52W High / Lowi | ₹4747.00 / ₹2500.00 |
| From 52W highi | -2.5% |
| Returns 1M/3M/6M/1Yi | 11.6% / 34.6% / 70.5% / 63.4% |
| Vol vs 20d avgi | 0.58x |
F Fundamental Scores
| Piotroski F-scorei | 5 / 6 (approx) |
| Altman Z-scorei | 3.65 (Z′ approx) |
| Beneish M-scorei | -2.46 (low, simplified) |
| Forensic riski | low (derived) |
| ROE / ROCEi | 21.2% (computed) / 26.1% (computed) |
| Revenue growth (3Y)i | 18.7% (4Y CAGR) |
| PAT growth (3Y)i | 33.7% (4Y CAGR) |
| Debt / Equityi | 0.15 (computed) |
| Promoter holdingi | 40.2% |
| FII / DII holdingi | 18.2% / 28.1% |
| NPMi | 11.3% (computed) |
| EPSi | 52.53 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹4,630.0 |
| EPS (TTM proxy)i | 52.53 |
| P/E (Screener ratios) | 87.2x |
| Market cap (Screener) | ₹61,960 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹248.0 |
| Dividend yield | 0.2% |
| Sales (latest)i | — |
| PAT (latest)i | ₹704 Cr (16.6% YoY) |
| Net debt (3Y)i | ₹258 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: FMCG & Consumer Goods
- Sub-sector: Unmapped
- Sector strength: 71.62
- Peer avg RS: 82.2% · Avg tech: 71.62 · Avg fund: 72.47
- Sector universe: 21 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹4,533 – ₹4,630 |
| Stop loss | ₹4,114 |
| Target 2M | ₹4,919 |
| Target 4M | ₹5,222 |
| Target 6M | ₹6,005 |
| Reward / Risk (4M) | 1.15× |
| Reward / Risk (6M) | 2.66× |
| Risk per share | ₹516 |
| Extension | NORMAL - -2.5% from 52w high |
| Suggested position size | 8% of portfolio |
Risk score breakdown: ATR 2.1% (+0.5) · Near high -2.5% (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 1684 | 21 | 230 | 17.14 |
| Mar 2026 | 1504 | 19 | 179 | 13.40 |
| Dec 2025 | 1547 | 17 | 155 | 11.57 |
| Sep 2025 | 1494 | 16 | 140 | 10.42 |
Rev QoQ +12.0% · YoY +11.8% · PAT QoQ +28.5% · YoY +75.6% · OPM vs 4Q avg +517 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 6228 | 18 | 704 | 52.53 |
| Mar 2026 | 6037 | 17 | 604 | 45.14 |
| Mar 2025 | 4843 | 14 | 346 | 25.83 |
| Mar 2024 | 4106 | 12 | 262 | 19.61 |
| Mar 2023 | 3133 | 11 | 220 | 16.48 |
4Y CAGR — Revenue 18.7% · PAT 33.7% · EPS 33.6%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 498 | 258 | 4995 |
| Mar 2025 | 750 | 552 | 4668 |
| Mar 2024 | 818 | 620 | 4104 |
Debt trend falling
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 743 | -266 | 477 |
| Mar 2025 | 363 | -171 | 192 |
| Mar 2024 | 166 | -226 | -60 |
OCF/PAT (latest FY) 1.06 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 6,228 Cr (YoY +3.2%); NetProfit: 704 Cr (YoY +16.6%); EPS: 52.53
- Quarterly: Sales last 3Q: 1,547, 1,504, 1,684 Cr; Net Profit last 3Q: 155, 179, 230 Cr
- Ratios: P/E: 87.2; ROCE: 24.2; ROE: 20.3; Div Yield: 0.19; Book Value: 248; Mkt Cap: 61,960
- Investors: Promoters 40.19% | FII 18.20% | DII 28.08% | Public 13.51%
Why selected: VCP-confirmed Stage 2 (vcp=83, inv=95.0); sector FMCG & Consumer Goods not in current top-10 rotation · Fundamentals, technical setup, and sector support reinforce high conviction on the stock.
⚖️ Full Disclaimer & Use Restrictions
Disclaimer: Not investment advice or a trading recommendation. Educational AI/rules-based market intelligence only. Use, replication, or trading action is at the user's own risk and legal obligation.
This report is provided strictly for educational, research, and learning purposes as part of a journey to understand how AI agents and rules-based agents can be applied to financial-market data. It is not investment advice, trading advice, portfolio advice, a research recommendation, or a solicitation to buy, sell, hold, short, or otherwise transact in any security, derivative, index, fund, or financial instrument. The information, scores, signals, narratives, charts, model outputs, and examples in this report must not be replicated, redistributed, automated, or used with any intent of trading, recommending trades, advising others, managing money, or making financial decisions. Anyone choosing to use, interpret, adapt, copy, replicate, distribute, or act on this information does so entirely at their own risk, responsibility, and legal and regulatory obligation. Agent Adda is not a SEBI-registered investment adviser, research analyst, portfolio manager, broker, or any other SEBI-registered market intermediary. Agent Adda, its creators, contributors, systems, agents, and associated persons accept no responsibility or liability for losses, damages, legal consequences, regulatory consequences, tax consequences, opportunity costs, or any other implications arising directly or indirectly from the use of this information by any person or organization. All market data can be delayed, incomplete, inaccurate, stale, or affected by corporate actions, liquidity, data-provider issues, model limitations, prompt limitations, or rule-design limitations. Users must consult qualified SEBI-registered professionals and independently verify all facts before making any financial or legal decision.